December 20, 2013 - An objector filed a notice of appeal against the settlement.
November 21, 2013 - The court approved the settlement, entered the orders approving the plan of allocation, the motion for attorneys’ fees and expenses, and dismissed the action with prejudice.

August 6, 2013 - The settlement was preliminarily approved by the court.

July 15, 2013 - Parties filed a stipulation of settlement.

December 19, 2011 - The court denied the motion to dismiss of certain defendants and granted the motion to dismiss of certain defendants. Those defendants are dismissed from the case without prejudice and lead plaintiff is granted leave to file a second amended complaint.

May 27, 2011 - Defendants filed a motion to dismiss.

March 11, 2011 - The lead plaintiff filed an amended complaint.

December 6, 2010 - Lead plaintiff and lead counsel were appointed.

November 22, 2010 - Lead plaintiff motions were filed.

September 21, 2010 - An investor in shares of Johnson & Johnson (NYSE: JNJ) filed a lawsuit in the U.S. District Court for the District of New Jersey against Johnson & Johnson and others over alleged violations of Federal Securities Laws in connection with certain allegedly false and misleading statements made between October 14, 2008 and July 21, 2010.

Johnson & Johnson, located in New Brunswick, NJ, is engaged in the research and development, manufacture and sale of a range of products in the health care field. Johnson & Johnson’s total revenue increased from $53.324 billion in 2006 to $61.897 billion in 2009. Its Net Income went from $11.053 billion in 2006 to $12.266 billion in 2009. According to the complaint the plaintiff alleges that Johnson & Johnson and certain of its officers and directors violated the Securities Exchange Act of 1934 between October 14, 2008 to July 21, 2010. More specifically, the complaint alleges that Johnson & Johnson failed to disclose and misrepresented the following material adverse facts which were known to defendants or recklessly disregarded by them.

The complaint alleges that starting in April of 2008, Johnson & Johnson received numerous consumer complaints that Tylenol products made at a manufacturing facility in Las Piedras, Puerto Rico exhibited a musty odor; Despite being aware of these complaints, Johnson & Johnson failed to conduct an adequate investigation and failed to notify the U.S. Food and Drug Administration ( FDA ) as required; Johnson & Johnson failed to take corrective action when foreign materials and contamination were found in a manufacturing facility in Fort Washington, Pennsylvania from May 2009 to April 2010. Similarly, Johnson & Johnson ignored 46 separate complaints of foreign materials in products made at that facility from June 2009 to April 2010; and in late 2008, defendants learned of potential problems with one of its Motrin products. Rather than issue a public recall, Johnson & Johnson sent contractors out to stores to buy the product back and told the contractors not to mention any recall and After the FDA learned of this phantom recall, it pressured Johnson & Johnson to publicly recall the products, so the lawsuit.

The plaintiff alleges that as a result of the blatant, systemic, and repeated failure of Johnson & Johnson to maintain proper manufacturing practices at their facilities, Johnson & Johnson has been forced to issue over eight separate recalls including dozens of products and hundreds of millions of individual packages. Further, so the complaint, Johnson & Johnson is now under investigation by the U.S. House of Representatives, the U.S. Senate, the U.S. Attorney's Office for the Eastern District of Pennsylvania, and multiple state Attorneys General offices. Shares of Johnson & Johnson (NYSE: JNJ) recently traded at $61.94 per share, down from its current 52 week high of $66.20 per share. JNJ shares traded as high as $71.55 per share during 2007.